Business development in the first quarter of 2010 was positive for ANZAG

02.02.2010 16:36

New legal regulations are having a stabilizing effect on pharmaceutical wholesalers

ANZAG shows positive development in the first quarter
Andreae-Noris Zahn AG (ANZAG), one of the leading German pharmaceutical wholesalers, increased its consolidated sales by 6.4 % to EUR 1.05 billion in the first quarter of the 2010 financial year (September 1st to November 30th, 2009). Earnings after taxes increased by EUR 1.5 million to EUR 7.1 million. Despite the continued difficult overall economic environment, the German pharmaceutical market grew by 5.5 % in the first three months of the 2010 financial year (previous year: 2.0 %).

Market sales in the prescription drug segment are the growth driver: in the current reporting period, the market volume in this product range increased by 6.4 %. The market for pharmacy-only medicines was weaker, with market sales declining by 1.5 % compared to the previous year. With an increase in sales of 7.0 %, the pharmaceutical wholesale market grew disproportionately to the pharmacy market. The reason for this is a decline in direct deliveries from industry. The share of direct business in the overall market was 16.6 % after 17.7 % in the same period of the previous year.